{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:14:06Z","timestamp":1787238846220,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["19-09086S"],"award-info":[{"award-number":["19-09086S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ejmech.2019.112019","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T11:32:43Z","timestamp":1577964763000},"page":"112019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in\u00a0vitro biological evaluation"],"prefix":"10.1016","volume":"189","author":[{"given":"Mohamed A.","family":"Said","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-702X","authenticated-orcid":false,"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar H.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Elgazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Kry\u0161tof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia H.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gratteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"Abou-Seri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.112019_bib1","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cam4.782","article-title":"Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer","volume":"5","author":"Fern\u00e1ndez-L\u00f3pez","year":"2016","journal-title":"Cancer. Med-US"},{"key":"10.1016\/j.ejmech.2019.112019_bib2","series-title":"World Health Statistics 2016: Monitoring Health for the SDGs Sustainable Development Goals","author":"Organization","year":"2016"},{"key":"10.1016\/j.ejmech.2019.112019_bib3","series-title":"Therapeutic Use of Carbonic Anhydrase Inhibitors and Their Multiple Drug Interactions, Pharmaceutical Biocatalysis: Fundamentals, Enzyme Inhibitors, and Enzymes in Health and Diseases","first-page":"73","author":"Angeli","year":"2019"},{"key":"10.1016\/j.ejmech.2019.112019_bib4","doi-asserted-by":"crossref","first-page":"111698","DOI":"10.1016\/j.ejmech.2019.111698","article-title":"Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors","volume":"183","author":"Vats","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib5","first-page":"3","article-title":"Advances in anti-cancer drug development targeting Carbonic Anhydrase IX and XII","volume":"5","author":"Mboge","year":"2015","journal-title":"Topics in Anticancer Res"},{"key":"10.1016\/j.ejmech.2019.112019_bib6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/med.21497","article-title":"Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one","volume":"38","author":"Supuran","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.112019_bib7","series-title":"Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy","first-page":"257","article-title":"Cell-cycle regulation","author":"Figel","year":"2018"},{"key":"10.1016\/j.ejmech.2019.112019_bib8","series-title":"Synergistic effect of BCL-2 inhibitor APG-2575 and CDK9 inhibitor in acute myeloid leukemia and DLBCL preclinical tumor models","author":"Fang","year":"2019"},{"key":"10.1016\/j.ejmech.2019.112019_bib9","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1021\/jm0605740","article-title":"4-Arylazo-3, 5-diamino-1 H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects","volume":"49","author":"Kry\u0161tof","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib10","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.7150\/jca.32628","article-title":"Cyclin-dependent kinases 4\/6 inhibitors in breast cancer: current status, resistance, and combination strategies","volume":"10","author":"Niu","year":"2019","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.ejmech.2019.112019_bib11","doi-asserted-by":"crossref","first-page":"126637","DOI":"10.1016\/j.bmcl.2019.126637","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015-2019)","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.112019_bib12","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/acsomega.7b00471","article-title":"A\u00a0simple isomerization of the purine scaffold of a kinase inhibitor, roscovitine, affords a four-to seven-fold enhancement of its affinity for four CDKs. Could this Be traced back to conjugation-induced stiffenings\/loosenings of rotational barriers?","volume":"2","author":"El Hage","year":"2017","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2019.112019_bib13","article-title":"Roscovitine in cancer and other diseases","volume":"3","author":"Cicenas","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejmech.2019.112019_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bioorg.2019.01.026","article-title":"New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: synthesis, CDK2 inhibition, QSAR and molecular docking studies","volume":"86","author":"El-Karim","year":"2019","journal-title":"Bioorg. Chem"},{"key":"10.1016\/j.ejmech.2019.112019_bib15","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1021\/acs.jmedchem.6b01254","article-title":"Cyclin-dependent kinase (CDK) inhibitors: structure\u2013activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines","volume":"60","author":"Coxon","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/cbdd.12330","article-title":"Arylazopyrazole AAP 1742 inhibits CDK s and induces apoptosis in multiple myeloma cells via mcl-1 downregulation","volume":"84","author":"Jorda","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2019.112019_bib17","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bmc.2015.03.025","article-title":"Novel arylazopyrazole inhibitors of cyclin-dependent kinases","volume":"23","author":"Jorda","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejmech.2018.10.068","article-title":"Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents","volume":"162","author":"Eldehna","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib19","doi-asserted-by":"crossref","first-page":"103102","DOI":"10.1016\/j.bioorg.2019.103102","article-title":"Synthesis, biological evaluation and in silico studies with 4-benzylidene-2-phenyl-5 (4H)-imidazolone-based benzenesulfonamides as novel selective carbonic anhydrase IX inhibitors endowed with anticancer activity","volume":"90","author":"Eldehna","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib20","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3390\/ijms20102484","article-title":"Novel diamide-based benzenesulfonamides as selective carbonic anhydrase IX inhibitors endowed with antitumor activity: synthesis, biological evaluation and in silico insights","volume":"20","author":"Abdelrahman","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2019.112019_bib21","doi-asserted-by":"crossref","first-page":"111768","DOI":"10.1016\/j.ejmech.2019.111768","article-title":"3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: synthesis, in\u00a0vitro biological evaluation and in silico insights","author":"Abo-Ashour","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejmech.2016.01.001","article-title":"Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents","volume":"109","author":"Alafeefy","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bioorg.2018.09.007","article-title":"Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in\u00a0vitro antitumor activity towards colon cancer","volume":"81","author":"Eldehna","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1039\/a802450b","article-title":"Utility of [(p-sulfonamidophenyl) azo] malononitrile in the synthesis of polyfunctionally substituted pyrimidine, pyrazole, isoxazole and pyridazine derivatives","volume":"23","author":"Hassanien","year":"1999","journal-title":"J.\u00a0Chem. Res."},{"key":"10.1016\/j.ejmech.2019.112019_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bioorg.2017.08.014","article-title":"Pyrazole-hydrazone derivatives as anti-inflammatory agents: design, synthesis, biological evaluation, COX-1, 2\/5-LOX inhibition and docking study","volume":"74","author":"Abdelgawad","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib26","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/jccs.200000176","article-title":"Utility of (p-Sulfonamidophenyl) azomalononitrile, and ethyl acetoacetate in synthesis of fused azole and azines derivatives II","volume":"47","author":"Hassanien","year":"2000","journal-title":"J.\u00a0Chin. Chem. Soc-Taip"},{"key":"10.1016\/j.ejmech.2019.112019_bib27","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1021\/jo01035a003","article-title":"Selective Bromination with copper (II) bromide1","volume":"29","author":"King","year":"1964","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib28","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1021\/acs.orglett.7b01115","article-title":"Rh\/DuanPhos-Catalyzed asymmetric hydrogenation of \u03b2-acetylamino vinylsulfides: an approach to chiral \u03b2-acetylamino sulfides","volume":"19","author":"Gao","year":"2017","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.112019_bib29","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/cmdc.201100304","article-title":"N-[2-Methyl-5-(triazol-1-yl) phenyl] pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of bcr-abl","volume":"6","author":"Arioli","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.112019_bib30","first-page":"36","article-title":"Studies with 2-arylhydrazono-3-oxopropanals: routes for the synthesis of pyridazine-3, 4-dicarboxylate and 3, 5-diaroylpyrazoles","volume":"17","author":"Al-Shiekh","year":"2008","journal-title":"Arkivoc"},{"key":"10.1016\/j.ejmech.2019.112019_bib31","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/jm049597+","article-title":"A\u00a0series of ligands displaying a remarkable agonistic\u2212 antagonistic profile at the adenosine A1 receptor","volume":"48","author":"Chang","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib32","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib33","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"JNCI (J. Natl. Cancer Inst.): J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2019.112019_bib34","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/ijc.22436","article-title":"HIF-1\u03b1 and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome","volume":"120","author":"Trastour","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2019.112019_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2019.112019_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11307-015-0885-x","article-title":"Evaluation of CAIX and CAXII expression in breast cancer at varied O 2 levels: CAIX is the superior surrogate imaging biomarker of tumor hypoxia","volume":"18","author":"Tafreshi","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.ejmech.2019.112019_bib37","doi-asserted-by":"crossref","first-page":"10692","DOI":"10.1021\/acs.jmedchem.6b01389","article-title":"Benzenesulfonamides incorporating flexible triazole moieties are highly effective carbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations","volume":"59","author":"Nocentini","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib38","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1021\/acs.jmedchem.5b01343","article-title":"Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX","volume":"58","author":"Leitans","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib39","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1073\/pnas.161301298","article-title":"Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells","volume":"98","author":"Whittington","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2019.112019_bib40","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1021\/acs.jmedchem.8b00625","article-title":"Discovery of \u03b2-adrenergic receptors blocker\u2013carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy","volume":"61","author":"Nocentini","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmech.2018.07.054","article-title":"Novel hydrazido benzenesulfonamides-isatin conjugates: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies","volume":"157","author":"Abo-Ashour","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib42","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/14756366.2019.1652282","article-title":"Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamides as carbonic anhydrase isoforms I and II inhibitors","volume":"34","author":"Al-Sanea","year":"2019","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib43","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1021\/jm4006884","article-title":"A\u00a0novel series of highly potent 2, 6, 9-trisubstituted purine cyclin-dependent kinase inhibitors","volume":"56","author":"Gucky","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejmech.2012.06.036","article-title":"Synthesis and in\u00a0vitro biological evaluation of 2, 6, 9-trisubstituted purines targeting multiple cyclin-dependent kinases","volume":"61","author":"Zatloukal","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib45","series-title":"Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval","author":"Teicher","year":"2013"},{"key":"10.1016\/j.ejmech.2019.112019_bib46a","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/14756366.2018.1547286","article-title":"Synthesis and in\u00a0vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents","volume":"34","author":"Eldehna","year":"2019","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib46b","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/molecules21060762","article-title":"Synthesis and cytotoxic activity of biphenylurea derivatives containing indolin-2-one moieties","volume":"21","author":"Eldehna","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.112019_bib47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/14756366.2017.1421181","article-title":"Novel [(3-indolylmethylene) hydrazono] indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in\u00a0vitro biological evaluation","volume":"33","author":"Eldehna","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejmech.2018.06.024","article-title":"Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells","volume":"155","author":"Ismail","year":"2018","journal-title":"Eur. J. Med. Chem emistry"},{"key":"10.1016\/j.ejmech.2019.112019_bib49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bioorg.2018.01.034","article-title":"Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer","volume":"77","author":"Almahli","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/14756366.2017.1417276","article-title":"One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells","volume":"33","author":"Eldehna","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib51","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14756366.2018.1477137","article-title":"Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in\u00a0vitro biological evaluation, and QSAR studies","volume":"33","author":"Sabt","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/14756366.2017.1279155","article-title":"Synthesis and in\u00a0vitro anti-proliferative activity of some novel isatins conjugated with quinazoline\/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents","volume":"32","author":"Eldehna","year":"2017","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib53","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/chem.201805039","article-title":"Phosphorus versus sulfur: discovery of benzenephosphonamidates as versatile sulfonamide-mimic chemotypes acting as carbonic anhydrase inhibitors","volume":"25","author":"Nocentini","year":"2019","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2019.112019_bib54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/14756366.2018.1512597","article-title":"Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms","volume":"33","author":"Nocentini","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.112019_bib55","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1002\/chem.201800941","article-title":"Deciphering the mechanism of human carbonic anhydrases inhibition with sulfocoumarins: computational and experimental studies","volume":"24","author":"Nocentini","year":"2018","journal-title":"Chem. Eur J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419311778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419311778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:05:44Z","timestamp":1759327544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419311778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":56,"alternative-id":["S0223523419311778"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.112019","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in\u00a0vitro biological evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.112019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112019"}}